FYB.F Formycon AG

Healthcare Biotechnology Frankfurt Exchange
14.64 EUR
Close of Nov 13, 2026
13.54 26.30
Market cap
EUR 259M
P/E
-
P/B
0.66x
ROE
-16.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is FYB.F undervalued?

Graham number

The Graham number of Formycon AG cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Formycon AG fundamental analysis

No fundamental analysis for Formycon AG yet.

Formycon AG stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Formycon AG

Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well as AHZANTIVE, Baiama, and Fovlya brand names. The company's pipeline includes u…

Full company profile